Adam Pearson, Chief Strategy Officer (CStO) of Astellas "At Astellas, we have a strong commitment to developing novel treatments for patients with cancer and have positioned Immuno-Oncology as a Primary Focus of our R&D strategy* 3. With iGPS, Kelonia has an elegant, cutting-edge in vivo delivery technology, and by combining with the ACCEL™ platform, we believe the collaboration will bring synergies between the two companies' breakthrough research and will ultimately lead to expansion of Astellas' portfolio and to delivery of innovative in vivo CAR-T cell therapies to cancer patients."